COMMIT/CCS-2 studies - Authors' reply

Lancet

Volumn 368, Issue 9536, 2006, Pages 642-643

  Chen, Zhengming ^a   Collins, Rory ^a   Peto, Richard ^a  

^a CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; FIBRINOLYTIC AGENT; HEPARIN; PLACEBO;

ACUTE HEART INFARCTION; BLEEDING; BLOOD CLOT LYSIS; CLINICAL TRIAL; DEATH; DRUG SAFETY; HEART REINFARCTION; HIGH RISK PATIENT; HUMAN; LETTER; PRIORITY JOURNAL; RANDOMIZATION; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STROKE; SYMPTOM;

EID: 33747165352     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)69236-2     Document Type: Letter

References (4)

1. COMMIT collaborative group. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1607-1621
2. Sabatine M., Cannon C., Gibson C., et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352 (2005) 1179-1189
3. Fox K., Goodman S., Anderson F., et al. From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). Eur Heart J 24 (2003) 1414-1424
4. Lagakos S. The challenge of subgroup analyses-reporting without distorting. N Engl J Med 354 (2006) 1667-1669